BioCentury
ARTICLE | Company News

PTC reveals price of steroid for DMD

May 12, 2017 3:57 AM UTC

PTC Therapeutics Inc. (NASDAQ:PTCT) said it intends to launch Duchenne muscular dystrophy (DMD) drug Emflaza deflazacort "in the coming weeks" at an anticipated annual net price of $35,000 for a 25 kg patient. It forecast 2017 Emflaza sales of $5-$10 million.

A company spokesperson told BioCentury the net price "takes into account the real-world dosing and utilization patterns as well as discounts" and other factors. She said the company has submitted the drug's wholesale acquisition cost (WAC) to regulators and expects it will be published soon. As an example, she said the WAC of a 6 mg tablet would be $43.60...

BCIQ Company Profiles

PTC Therapeutics Inc.